Prospective Registration of Patient Data and Quality of Life in Eye Melanoma Patients
- Conditions
- Uveal Melanoma
- Interventions
- Other: Quality of life questionnairesOther: Discrete choice experimentOther: Shared decision-making analysisOther: Impact of side-effects analysis
- Registration Number
- NCT05377957
- Lead Sponsor
- Leiden University Medical Center
- Brief Summary
PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.
- Detailed Description
PROQEM is a prospective observational cohort study wherein patients with uveal melanoma are registered at diagnosis and are requested to fill in an array of questionaires before treatment and at 3, 6, 12, 24, 36 and 60 months after treatment. A comprehensive overview of the impact of their disease and treatment on quality of life is obtained by systematic assessment of the psychological impact of the initial diagnosis, eye symptoms, physical, emotional, social and role functioning.
In addition, the PROQEM has a substudy called the PROQEM-pco (Preferences, Choices and Outcomes) for the subgroup of patients who are eligible for both proton therapy and enucleation. They are invited to participate in research on patient preferences and shared decision-making. The consultations wherein the treatment decision is made are audiotaped and data on perceived shared decision-making, preferences, decision satisfaction and -regret are collected by questionaires at baseline and in the first 36 months after treatment.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Age ≥18 years
- Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body
- No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver
- Treatment by brachytherapy, proton therapy or enucleation
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Proton therapy Discrete choice experiment Uveal melanoma patients treated with proton therapy Enucleation Quality of life questionnaires Uveal melanoma patients treated with enucleation Brachytherapy Quality of life questionnaires Uveal melanoma patients treated with Ruthenium-106 plaque brachytherapy Proton therapy Quality of life questionnaires Uveal melanoma patients treated with proton therapy Proton therapy Impact of side-effects analysis Uveal melanoma patients treated with proton therapy Enucleation Discrete choice experiment Uveal melanoma patients treated with enucleation Enucleation Impact of side-effects analysis Uveal melanoma patients treated with enucleation Proton therapy Shared decision-making analysis Uveal melanoma patients treated with proton therapy Enucleation Shared decision-making analysis Uveal melanoma patients treated with enucleation
- Primary Outcome Measures
Name Time Method Uveal melanoma-related quality of life 5 years EORTC QLQ-OPT30
Health-related quality of life 5 years EORTC QLQ-C30
General quality of life 5 years EQ-5D-5L
Impact of the diagnosis and treatment of uveal melanoma on mental health 2 years Impact of events scale
- Secondary Outcome Measures
Name Time Method Shared decision-making 1 year Audiotape, iSHARE, satisfaction with decision scale, decision regret scale
Patient preferences for outcomes of proton therapy and enucleation Cross-sectional at baseline Discrete choice experiment
Impact of side-effects of treatment for uveal melanoma 3 years Questionnaire specifically developed for uveal melanoma
Trial Locations
- Locations (1)
Leiden University Medical Center
🇳🇱Leiden, Zuid-Holland, Netherlands